|
2023 Conference Publication P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate- and poor-risk metastatic germ cell tumours (GCTs)Zebic, Danka, Stockler, Martin R., Martin, Andrew James, Pashankar, Farzana D., Tran, Ben, Mazhar, Danish, Huddart, Robert A., Wheater, Matthew, Walpole, Euan Thomas, Dunwoodie, Elaine, Feldman, Darren R., Birtle, Alison Jane, Stevanovic, Amanda Gwendolyn, Wyld, David, Hanning, Fritha J., Grimison, Peter S. and Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2023). P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate- and poor-risk metastatic germ cell tumours (GCTs). 2023 ASCO Genitourinary Cancers Symposium, San Francisco, CA United States, 16-18 February 2023. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.6_suppl.tps431 |
|
2023 Conference Publication Evolution: Phase II study of radionuclide <sup>177</sup>Lu-PSMA-617 therapy versus <sup>177</sup>Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (mCRPC; ANZUP 2001)Sandhu, Shahneen, Subramaniam, Shalini, Hofman, Michael S., Stockler, Martin R., Martin, Andrew James, Pokorski, Izabella, Goh, Jeffrey C., Pattison, David A., Dhiantravan, Nattakorn, Gedye, Craig, Rutherford, Natalie K., Joshua, Anthony M., Tan, Thean Hsiang, Kirkwood, Ian D., Lee, Sze Ting, Weickhardt, Andrew James, Alipour, Ramin, Nguyen, Andrew, Davis, Ian D., Emmett, Louise and The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2023). Evolution: Phase II study of radionuclide 177Lu-PSMA-617 therapy versus 177Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (mCRPC; ANZUP 2001). 2023 ASCO Genitourinary Cancers Symposium, San Francisco, CA United States, 16-18 February 2023. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.6_suppl.tps271 |
|
2023 Conference Publication An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediateand poor-risk metastatic germ cell tumours (GCTs)Zebic, Danka, Stockler, Martin R., Martin, Andrew James, Pashankar, Farzana D., Tran, Ben, Mazhar, Danish, Huddart, Robert A., Wheater, Matthew, Walpole, Euan Thomas, Dunwoodie, Elaine, Feldman, Darren R., Birtle, Alison Jane, Stevanovic, Amanda Gwendolyn, Wyld, David, Hanning, Fritha J. and Grimison, Peter S. (2023). An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediateand poor-risk metastatic germ cell tumours (GCTs). Genitourinary Cancers Symposium, Online, 16-18 February 2023. Philadelphia, PA United States: Lippincott Williams & Wilkins. |
|
2022 Conference Publication P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs)Zebic, Danka, Stockler, Martin R., Martin, Andrew, Pashankar, Farzana, Ben Tran,, Mazhar, Danish, Huddart, Robert, Wheater, Matthew, Walpole, Euan, Dunwoodie, Elaine, Feldman, Darren, Birtle, Alison, Stevanovic, Amanda G., Wyld, David, Hanning, Fritha J. and Grimison, Peter S. (2022). P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs). Clinical Oncology Society of Australia (COSA) 49th Annual Scientific Meeting, Brisbane, QLD, Australia, 2-4 November 2022. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.13869 |
|
2022 Conference Publication DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)-A randomized phase 3, double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiationNiazi, Tamim, McBride, Sean Matthew, Williams, Scott, Davis, Ian D., Stockler, Martin R., Martin, Andrew James, Bracken, Karen, Roncolato, Felicia, Horvath, Lisa, Sengupta, Shomik, Martin, Jarad, Lim, Tee, Hughes, Simon, McDermott, Raymond S., Catto, James W. F., Kelly, Paul J., Parulekar, Wendy R., Morgan, Scott Carlyle, Rendon, Ricardo A. and Sweeney, Christopher (2022). DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)-A randomized phase 3, double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Electr Network, Jun 03-07, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. doi: 10.1200/JCO.2022.40.6_suppl.TPS284 |
|
2022 Conference Publication TheraP: <sup>177</sup>Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel-Overall survival after median follow-up of 3 years (ANZUP 1603)Hofman, Michael S., Emmett, Louise, Sandhu, Shahneen, Iravani, Amir, Joshua, Anthony M., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Francis, Roslyn J., Gedye, Craig, Rutherford, Natalie K., Zhang, Alison Yan, McJannett, Margaret Mary, Stockler, Martin R., Williams, Scott, Martin, Andrew James and Davis, Ian D. (2022). TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel-Overall survival after median follow-up of 3 years (ANZUP 1603). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Virtual, 3-7 June 2022. Philadelphia, PA USA: Lippincott Williams & Wilkins. |
|
2022 Conference Publication PSMA PET and FDG PET as predictors of response and prognosis in a randomized phase 2 trial of <SUP>177</SUP>Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic, castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603)Buteau, James Patrick, Martin, Andrew James, Emmett, Louise, Iravani, Amir, Sandhu, Shahneen Kaur, Joshua, Anthony M., Zhang, Alison Yan, Francis, Roslyn J., Scott, Andrew Mark, Azad, Arun, McJannett, Margaret Mary, Stockler, Martin R., Williams, Scott, Davis, Ian D. and Hofman, Michael S. (2022). PSMA PET and FDG PET as predictors of response and prognosis in a randomized phase 2 trial of 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic, castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603). ASCO Genitourinary Cancers Symposium, Electr Network, Feb 17-19, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. doi: 10.1200/JCO.2022.40.6_suppl.010 |
|
2022 Conference Publication SUB-urothelial durvalumab injection: 1 (SUBDUE-1)-Results from the first nine urothelial cancer patients using a dose-escalation scheduleHayne, Dickon, Swarbrick, Nicole, McCombie, Stephen, Moe, Andrew, Hawks, Cynthia, Viswambaram, Pravin, Conduit, Ciara, Liow, Elizabeth Chien Hern, Spalding, Lisa, Bothe, Jarrad, Ferguson, Tom, Martin, Andrew James, Davis, Ian D. and Redfern, Andrew David (2022). SUB-urothelial durvalumab injection: 1 (SUBDUE-1)-Results from the first nine urothelial cancer patients using a dose-escalation schedule. ASCO Genitourinary Cancers Symposium, Electr Network, Feb 17-19, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. doi: 10.1200/JCO.2022.40.6_suppl.483 |
|
2022 Conference Publication ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901)Emmett, Louise, Subramaniam, Shalini, Martin, Andrew James, Zhang, Alison Yan, Yip, Sonia, Crumbaker, Megan, Rana, Nisha, Francis, Roslyn J., Hofman, Michael S., Joshua, Anthony M., Sandhu, Shahneen Kaur, Azad, Arun, Gedye, Craig, Weickhardt, Andrew James, Goh, Jeffrey C., Ng, Siobhan, Voskoboynik, Mark, McJannett, Margaret Mary, Stockler, Martin R. and Davis, Ian D. (2022). ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901). ASCO Genitourinary Cancers Symposium, Electr Network, Feb 17-19, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. doi: 10.1200/JCO.2022.40.6_suppl.TPS205 |
|
2022 Conference Publication Quantifying molecular imaging patterns of treatment response or progression using a novel traffic light workflow within a prospective phase I/II trial of 1<SUP>77</SUP>LuPSMA-617 and NOX66 (LuPIN)Pathmanandavel, Sarennya, Crumbaker, Megan, Yam, Andrew O., Nguyen, Andrew, Niman, Remy, Wilson, Peter, Sharma, Shikha, Ayers, Maria, Eu, Peter, Stockler, Martin R., Martin, Andrew James, Joshua, Anthony M. and Emmett, Louise (2022). Quantifying molecular imaging patterns of treatment response or progression using a novel traffic light workflow within a prospective phase I/II trial of 177LuPSMA-617 and NOX66 (LuPIN). ASCO Genitourinary Cancers Symposium, Electr Network, Feb 17-19, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. doi: 10.1200/JCO.2022.40.6_suppl.166 |
|
2022 Conference Publication INTEGRATE IIb: A randomized phase III open label study of regorafenib plus nivolumab versus standard chemotherapy in refractory advanced gastroesophageal cancer (AGOC)Pavlakis, Nick, Shitara, Kohei, Sjoquist, Katrin Marie, Martin, Andrew James, Jaworski, Anthony, Yip, Sonia, Oh, Do-Youn, Moehler, Markus H., Bekaii-Saab, Tanios S., Simes, John and Goldstein, David (2022). INTEGRATE IIb: A randomized phase III open label study of regorafenib plus nivolumab versus standard chemotherapy in refractory advanced gastroesophageal cancer (AGOC). ASCO Gastrointestinal Cancers Symposium, San Francisco Ca, Jan 20-22, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. doi: 10.1200/JCO.2022.40.4_suppl.TPS366 |
|
2021 Conference Publication P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumors (GCTs)Subramaniam, Shalini, Toner, Guy C., Stockler, Martin R., Martin, Andrew James, Pashankar, Farzana D., Tran, Ben, Jeffery, Mark, Mazhar, Danish, Huddart, Robert A., Walpole, Euan Thomas, Stevanovic, Amanda Gwendolyn, Wyld, David, Hanning, Fritha J., Wheater, Matthew James, Balagtas, Jay R., Troon, Simon, Birtle, Alison Jane, White, Jeff D. and Grimison, Peter S. (2021). P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumors (GCTs). ASCO Genitourinary Cancers Symposium (GU ASCO), Online, 11-13 February 2021. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2021.39.6_suppl.TPS390 |
|
2021 Conference Publication 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel: Updated results including progression-free survival (PFS) and patient-reported outcomes (PROs) (TheraP ANZUP 1603)Hofman, Michael S., Emmett, Louise, Sandhu, Shahneen Kaur, Iravani, Amir, Joshua, Anthony M., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Ng, Siobhan, Francis, Roslyn J., Gedye, Craig, Rutherford, Natalie K., Zhang, Alison Yan, McJannett, Margaret Mary, Stockler, Martin R., Violet, John A., Williams, Scott, Martin, Andrew James and Davis, Ian D. (2021). 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel: Updated results including progression-free survival (PFS) and patient-reported outcomes (PROs) (TheraP ANZUP 1603). ASCO Genitourinary Cancers Symposium (GU ASCO), Online, 11-13 February 2021. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2021.39.6_suppl.6 |
|
2020 Conference Publication DASL-HiCaP: Darolutamide augments standard therapy for localised very high-risk cancer of the prostate (ANZUP1801). A randomised phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiationNiazi, T., Williams, S., Davis, I. D., Stockler, M. R., Martin, A., Bracken, K., Roncolato, F., McJannett, M., Horvath, L., Sengupta, S., Hughes, S., McDermott, R., Catto, J., Kelly, P., Vapiwala, N., Parulekar, W. R., Morgan, S., Rendon, R. A. and Sweeney, C. (2020). DASL-HiCaP: Darolutamide augments standard therapy for localised very high-risk cancer of the prostate (ANZUP1801). A randomised phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation. ESMO Virtual Congress, Electr Network, Sep 19-Oct 18, 2020. AMSTERDAM: ELSEVIER. doi: 10.1016/j.annonc.2020.08.2088 |
|
2020 Conference Publication P3BEP (ANZUP 1302): an international randomized phase III trial of accelerated versus standard BEP chemotherapy for adult and pediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs)Subramaniam, Shalini, Toner, Guy C., Stockler, Martin R., Martin, Andrew James, Pashankar, Farzana D., Frazier, A. Lindsay, Mazhar, Danish, Ford, Kate, Walpole, Euan Thomas, Stevanovic, Amanda Gwendolyn, Wyld, David, Troon, Simon, Hanning, Fritha J., Birtle, Alison Jane, Wheater, Matthew James, Huddart, Robert A., White, Jeff D., Spunt, Sheri L. and Grimison, Peter S. (2020). P3BEP (ANZUP 1302): an international randomized phase III trial of accelerated versus standard BEP chemotherapy for adult and pediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs). Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), San Francisco, CA USA, 13-15 February 2020. Alexandria, VA: American Society of Clinical Oncology. |
|
2017 Conference Publication Physical Activity for Women with Metastatic Breast Cancer: A Pilot RCTYee, Jasmine, Davis, Glen M., Hackett, Daniel, Beith, Janem M., Wilcken, Nicholas, Currow, David, Emery, Jon, Phillips, Jane, Martin, Andrew, Hui, Rina, Harrison, Michelle, Segelov, Eva and Kilbreath, Sharon L. (2017). Physical Activity for Women with Metastatic Breast Cancer: A Pilot RCT. HOBOKEN: WILEY. |
|
2017 Conference Publication P3BEP (ANZUP 1302): An International Randomised Phase III Trial of Accelerated Versus Standard BEP Chemotherapy for Adult and Pediatric Male and Female Patients With Intermediate and Poor-Risk Metastatic Germ Cell Tumours (GCTS)Wong, Nicole, Nayar, Namrata, Lawrence, Nicola, Stockler, Martin, Martin, Andrew, Yip, Sonia, Yeung, Annie, Friedlander, Michael, Mazhar, Danish, Pashankar, Farzana, Quinn, David, Walker, Roderick, Winstanley, Mark, Weickhardt, Andrew, Hanning, Fritha, Stevanovic, Amanda, Davis, Ian, Toner, Guy and Grimison, Peter (2017). P3BEP (ANZUP 1302): An International Randomised Phase III Trial of Accelerated Versus Standard BEP Chemotherapy for Adult and Pediatric Male and Female Patients With Intermediate and Poor-Risk Metastatic Germ Cell Tumours (GCTS). HOBOKEN: WILEY. |
|
2017 Conference Publication The Chest Australia Trial: A Phase II Randomised Controlled Trial of an Intervention to Reduce Time to Consult with Symptoms of Lung CancerEmery, Jon, Murray, Sonya, Campbell, Neil, Walter, Fiiona M., Mazza, Danielle, Habgood, Emily, Kutzer, Yvonne, Martin, Andrew, Goodall, Stephen, Barnes, David and Murchie, Peter (2017). The Chest Australia Trial: A Phase II Randomised Controlled Trial of an Intervention to Reduce Time to Consult with Symptoms of Lung Cancer. HOBOKEN: WILEY. |
|
2017 Conference Publication Predicting Chemotherapy Toxicity in Older Adults: Comparing the Value of the Carg Toxicity Score With Oncologists' Estimates of ToxicityMoth, Erin B., Kiely, Belinda E., Naganathan, Vasikaran, Martin, Andrew, Stefanic, Natalie, Beale, Philip, Grimison, Peter and Blinman, Prunella (2017). Predicting Chemotherapy Toxicity in Older Adults: Comparing the Value of the Carg Toxicity Score With Oncologists' Estimates of Toxicity. HOBOKEN: WILEY. |
|
2017 Conference Publication Accuracy and Prognostic Significance of Oncologists' Estimates and Scenarios for Survival Time in A Randomised Phase II Trial of Regorafenib in Advanced Gastric CancerVasista, Anuradha, Martin, Andrew, Pavlakis, Nick, Sjoquist, Katrin M., Snow, Stephanie, Jonker, Derek, Chua, Yu Jo, Epstein, Richard, Bonaventura, Tony, Khasraw, Mustafa, Varma, Suresh, Singhal, Nimit, Ransom, David, Aubin, Francine, Burkes, Ronald, Lim, Howard, Lemay, Frederic, Begbie, Stephen, Stockler, Martin and Kiely, Belinda (2017). Accuracy and Prognostic Significance of Oncologists' Estimates and Scenarios for Survival Time in A Randomised Phase II Trial of Regorafenib in Advanced Gastric Cancer. HOBOKEN: WILEY. |
